Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
doi: 10.1007/s00125-022-05772-9 61 Garcia-HernandezPArechavaleta-Granell MdelRYamamotoJFalahatiAGonzalez-GalvezGGrupo de Investigadores de L-eM
Semaglutide is FDA-approved for type 2 diabetes management (Ozempic, Rybelsus), cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease (Ozempic), chronic weight management in obesity or overweight with comorbidities (Wegovy), and cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight (Wegovy)
For patients already on hormone replacement therapy (HRT), the notion of reducing senescent cell load may complement hormone optimisation by reducing the age burden on the tissues
The cost of covering obesity medications may be significant, the trio agreed, but the cost of not covering them could be even higher
